Oxford Investment Opportunity Network

The following five companies are seeking investment via the Network as a result of the 27 February, 2007 investment meeting at Oxford Science. The descriptions available summarise the investment proposal made by the company. The information is provided by the company and has not been vetted in any way by OION.

If you are interested in receiving further information on any of the companies then please contact us.

Company A, assisted by Westminster, Reading, and Imperial College and Vodafone Research, Company A is developing UK’s first multi-discipline telehealthcare system to reduce hospital admissions and bed-days of heart failure and chronic obstructive pulmonary disease (COPD) by 50%. These patients make the greatest single demand on PCTs. A DoH £30m telehealthcare trial starts April 2007 and Company A intends to play a major part. Company A’s, patented technologies (acquired from Intelligent Clothing Ltd. www.intelligentclothing.com), comprise a mobile phone platform for wearable monitoring and innovative web-based software to enable Community Matrons to manage home-based patients. Company A has a pan USA/EU executive with a marketing strategy encompassing both hospital adult “Telehealthcare” patients and paediatric and maternal “Wellness” retail products. £1.5m is sought to match DTI/EU grants and to help finance production and commercial roll out. A VP and Director of Business Development in O2 and Oracle have expressed an interest to collaborate.

Company B’s is developing unique, mass market, disposable medical devices to treat female incontinence. Incontinence affects at least 25% of the female population across the age groups 18-85. On a conservative estimate there are over 100 million sufferers in the developed world. The estimated worldwide spend on managing and alleviating incontinence is around £20 billion The market potential for the Company B products is estimated at 170 million units per annum with a retail sales value of £450 million.The designs and technology are protected by one granted patent and three in application. Funding is now required to conduct large user trials and launch the products in a test market ahead of full commercialisation.Women with incontinence are often reluctant to visit a clinician to seek treatment, due to embarrassment. To overcome this barrier Company B’s lead device will be sold in pharmacies, supermarkets and over the internet. It is a mass market product, with no equivalent competitors. Company B is led by a management team with expert knowledge of the clinical issues and extensive market experience. Company B has is seeking to raise up to £1.4million in this round of which £1million has already been committed by VCs.

Company C is developing an innovative non-invasive platform technology to exploit the diagnostic properties of the eye. The primary product will be a non-invasive glucose meter for people with diabetes that will have the look and feel of a mobile phone. The user will simply look into it to measure their glucose level. This meter will eliminate the need for the more painful traditional ‘finger stick’ solutions which have generated a £3.2bn global market that is growing at over 10% per annum. Company C’s glucose meter has successfully achieved technical and clinical targets with independently reviewed results. The product is intended to be easy to use, non-invasive, painless, have no side effects and is expected to cost less than the current finger stick solution. In addition, Lein has already received revenues from sales of its technology into a second, complimentary market.In 2004 the company received seed funding from specialist early stage technology investor Seven Spires. This was used to support the development of working prototypes for ‘proof of concept’ trials. Following the success of these trials we are now looking to raise a further investment of £1.0 – 1.5m to complete the next technical and clinical milestones.

Company D is a Drug Discovery Tools Company developing a range of products based upon P450 liver enzymes. P450s are responsible for a third of drug failures and 56% of adverse drug reactions. Approximately 5 million P450 tests are conducted per annum as part of the drug discovery process within the major pharmaceutical and service companies worth £200million.Company D is producing a range of consumable arrays based upon its patented P450 technology and in 2006 it secured a £1.8m project with the DTI to develop its 2nd generation platform and is partnering with Imperial College, RAL and gsk. The Company was formed in 2001 and is a spin-out from Imperial College, London. The Company is currently raising £5m, of which it has secured £3.25m from existing investors.

Company E is a software business with a team possessing extensive, relevant industry experience in technology, sales and management, start-ups and corporates. Company E has developed a product suite called "InSite". InSite is a customer-proven solution for system monitoring, reporting and alerting for mid to large companies, offered at a compelling price point and available as licensed software or as a managed service. Deploying InSite delivers business benefits including cost savings and improved profitability, operational efficiencies and customer service. Matt Talbot, Operations Director, Tiscali UK: "Feedback from our users has been very positive. We have benefited from a significant increase in operational efficiency which has meant a fast payback on our investment. ”Guy Willner, CEO of IX Europe: "We saw benefits from the Company E solution as soon as we switched it on, with payback on our investment in 3 or 4 months." Company E is working with specialist resellers, growing the sales pipeline, and is in discussion with Oracle for a commercial/technical deal. IDC predicts that the market for enterprise systems management software will grow from $9 billion in 2006 to $13 billion in 2010. Company E seeks an investment of £1.2m to expand sales and accelerate development plans.